Key result
Bolus-administered nitroglycerin (n=20) and prostaglandin E1 (n=20) significantly reduced mean arterial pressure and systemic vascular resistance without deteriorating cardiac index.
Why the study?
Does intravenous bolus injection of nitroglycerin compared to prostaglandin E1 improve hemodynamics in elderly patients with atherosclerotic disease?
Does intravenous bolus injection of nitroglycerin compared to prostaglandin E1 improve hemodynamics in elderly patients with atherosclerotic disease?
Bolus-administered nitroglycerin and prostaglandin E1 provide beneficial vasodilating effects without compromising cardiac function in elderly patients with atherosclerotic disease.
Answers are grounded in this paper and cite their sources.
May support acute vasodilation without cardiac compromise in elderly atherosclerotic patients; hypothesis-generating, needs randomized confirmation.
To evaluate the hemodynamic effects of vasodilators in elderly patients with atherosclerotic disease, systemic hemodynamics were examined during cardiac catheterization study. After the intravenous bolus injection of nitroglycerin (NTG, 5 µg/kg, n = 20) or prostaglandin E1 (PGE1, 0.2 µg/kg, n = 20), significant reduction of mean arterial pressure, pulmonary capillary wedge pressure (PCWP), systemic vascular resistance index (SVRI), and rate-pressure product (RPP) was observed. In contrast, cardiac index and stroke index were not significantly deteriorated in either group. In conclusion, bolus-administered NTG and PGE1 had beneficial vasodilating effects without harmful impact on cardiac functions in elder patients with atherosclerotic disease.
No takes yet. Share an insight, caveat, or question.
Utoh et al. (2005) studied Atherosclerotic disease (n=40). Nitroglycerin vs. Prostaglandin E1 (0.2 µg/kg intravenous bolus) was evaluated on Systemic hemodynamics including mean arterial pressure, pulmonary capillary wedge pressure, systemic vascular resistance index, and rate-pressure product. Bolus-administered nitroglycerin (n=20) and prostaglandin E1 (n=20) significantly reduced mean arterial pressure and systemic vascular resistance without deteriorating cardiac index.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: